SKYEPHARMA REACQUIRES EUROPEAN RIGHTS FOR DEPOBUPIVACAINE

SkyePharma PLC announces that it has completed negotiations with Mundipharma International Holdings Limited the result of which is that SkyePharma will reacquire the rights for the marketing and distribution of DepoBupivacaine in Europe and other international markets excluding the USA, Canada and Japan. SkyePharma will also obtain rights to the clinical data from the Phase II trials of DepoBupivacaine. This is expected to simplify the ongoing divestment process of SkyePharma's injectables unit. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/4945/118/)